Immutep LtdASX: IMM

EFTISARC-NEO Survival Data reported in CTOS 2026 Abstract

· Issued by Immutep Ltd via ASX

Filed with ASX · · 3 pages · English

Summary by 6ix AI

The data demonstrate encouraging preliminary long-term outcomes in patients with resectable soft tissue sarcoma, with notable disease-free survival rates. Investigators concluded that the combination of efti, KEYTRUDA, and radiotherapy as neoadjuvant therapy shows promise for further trials.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO • First survival data from EFTISARC-NEO, released in CTOS 2026 Abstract, demonstrate encouraging preliminary long-term outcomes in patients with resectable soft tissue sarcoma (STS). • With a median...

Immutep Ltd on 6ix

Story so far

Earlier from Immutep

Later from Immutep

All Immutep news releases